According to Nova one advisor, the global Orthobiologics market was valued at USD 5.11 billion in 2021 and it is expected to hit around USD 7.18 billion by 2030 with a CAGR of 4.10% during the forecast period 2022 to 2030.
According to Nova one advisor, the global Orthobiologics market was valued at USD 5.11 billion in 2021 and it is expected to hit around USD 7.18 billion by 2030 with a CAGR of 4.10% during the forecast period 2022 to 2030.
Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7435
Orthobiologics encompass a broad range of technologies with a biological or biochemical component. Examples include biologic factors delivered through a device, bone graft materials, cell therapies, and resorbable scaffolds to reinforce soft tissue. Rise in usage of orthobiologics products and orthopedic devices, and the integration of biology and biochemistry in the treatment of bone and soft tissue injuries are driving the orthobiologics market. Orthobiologics are medications that speed up the body’s natural healing process. They can help repair osteoarthritis damage as well as accelerate the recovery of strained muscles, tendons, and ligaments. Orthobiologics are made with components that are naturally found in the human body. Rise in prevalence of inflammatory conditions such as osteoarthritis and tendinitis along with increase in participation in a sports activity that can lead to ligament or muscle injury in teenagers and young adults is expected to drive the global orthobiologics market during the forecast period. Orthobiologics, which has the potential to accelerate the healing process for pain and injuries, provides solutions and hope for people who want to live a pain-free life.
Report Scope of the Orthobiologics Market
| Report Coverage | Details |
| Market Size | USD 7.18 Billion by 2030 |
| Growth Rate | CAGR of 4.10% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product, Application, End-user and Region, |
| Companies Mentioned |
|
Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7435
Surge in Sports Injuries to Drive Global Orthobiologics Market
Sports injuries have become a major concern for athletes. The musculoskeletal system, which consists of the muscles, tendons, ligaments, fascia, nerves, bones, and tissues, is involved in sports injuries. Falls, excessive exertion, and fractures are the primary causes of these injuries. Lower and upper extremities suffer the majority of sports-related injuries and muscle injuries. Orthobiologics, such as stem cells, are used to treat common, acute, and chronic sports injuries. Year-round participation in a single sport is the most significant cause of increase in youth injuries. Rugby, combat sports, field hockey, basketball, and handball account for the most number of hand injuries.
In the last few decades, there has been an increase in sports participation by children and adolescents at an early age in the U.S. There has also been a rise in specialization in sports at a very early age. This trend has contributed to the patterns of injuries seen in young athletes. Injuries previously observed in mature athletes are now being reported in young athletes. According to a study published by the National Library of Medicine, 3.5 million youth under the age of 15 receive medical care each year in the U.S. for injuries sustained during sports practice.
Increase in Demand for Non-surgical Treatments for Osteoarthritis to Propel Viscosupplements Segment
In terms of product, the viscosupplements segment held significant market share in 2021. Increase in demand for non-surgical treatments for osteoarthritis, rise in prevalence of lifestyle-induced disorders, and advancements in hyaluronic acid-based therapies are expected to drive the viscosupplements segment during the forecast period. Viscosupplements demonstrate clinical efficacy and is the most effective treatment for knee osteoarthritis. Osteoarthritis is the most common joint disorder in the U.S., affecting nearly 27 million people. Osteoarthritis of the knee alone affects 10% of men and 13% of women over the age of 60. Viscosupplementation can significantly reduce pain while improving joint mobility and function, making daily activities and even athletic or strenuous exercise less painful. Manufacturers of viscosupplementation devices are striving to develop and get approval for new medicines to treat osteoarthritis of the elbow, hip, and knee.
Rise in Number of Spinal and Sports-related Injuries to Boost Demand for Spinal Fusion Devices
The spinal fusion segment accounted for the largest share of the global orthobiologics market in 2021. The segment is expected to be driven by the increase in number of spinal injuries and sports-related injuries during the forecast period. Demand for spinal fusion devices has been rising across the globe. Majority of spinal cord injuries are caused by avoidable incidences such as car accidents, falls, or violence. Traumatic spinal injury (TSI) occurs when bony, ligamentous, and/or neurologic structures of the spinal column are injured and result in significant morbidity and mortality.
Provision of Majority of Orthopedic Surgeries to Drive Hospitals Segment
In terms of end-user, the hospitals segment is projected to account for a major share of the global orthobiologics market during the forecast period. Orthopedic surgery is performed in hospitals on various parts such as the shoulder, ankle, hip, knee, wrists, elbow, and spine, depending on the type of injury or damage. Knee joint replacement, arthroscopy, pediatric orthopedic, and other minimally invasive orthopedic surgeries are the most commonly recommended procedures. Hence, the hospitals segment is likely to capture significant market share during the forecast period. Surgeries were traditionally performed in hospitals; however, advances in technology, anesthesia, and pain control now allow physicians to perform certain procedures in an orthopedic clinic center. This is projected to drive the orthopedic clinics segment in the next few years.
Regional Outlook of Global Orthobiologics Market
North America accounted for the largest share of around 45.9% of the global orthobiologics market in 2021. It is projected to be a highly lucrative region of the global market during the forecast period. Increase in demand for orthobiologics products, highly developed healthcare system, and availability of advanced therapy for orthopedic treatment are the factors driving the market in North America. The U.S. dominated the market in North America in 2021 due to the significant increase in spine injuries caused by falls and accidents in the country. According to the Department of Health and Human Services, two million people in the country suffer from sports-related injuries every year. There is also a greater understanding of orthobiologics and its benefits, such as accelerated healing capabilities, faster recoveries, and fewer hospital visits.
The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Rise in geriatric and target patient population, high incidence of osteoarthritis and obesity, increase in government healthcare spending, and improved healthcare infrastructure are the major factors driving the market in the region. Furthermore, Asia Pacific was the leading market for non-industry-sponsored osteoarthritis trials, accounting for a significant share in 2021.
Key Developments in Global Orthobiologics Market
- In March 2022, MTF Biologics and Orthofix Medical, Inc. extended their orthobiologics collaboration. The agreement extends Orthofix’s exclusive marketing rights to the Trinity allograft line till 2032 and includes an expansion agreement for the development of a demineralized bone matrix (DBM) that Orthofix will market under the Legacy brand name.
- In November 2020, OssDsign expanded into the large and rapidly growing orthobiologics segment, thereby taking the first transformative step toward becoming a broader orthopedic player. OssDsign expanded its product portfolio with the addition of a next-generation nanosynthetic bone graft substitute designed to treat skeletal defects.
- In March 2016, Zimmer Biomet entered into an exclusive global distribution agreement with recently formed upstart CelgenTek Innovations to distribute its fracture fixation system and a bone-void filler
Some of the prominent players in the Orthobiologics Market include:
- Alphatec Spine, Inc.
- Arthrex
- Bioventus
- DePuy Synthes
- Exactech, Inc.
- Globus Medical, Inc.
- Integra Life Sciences
- Johnson & Johnson
- Medtronic plc
- MTF Biologics
- RTI Surgical, Inc.
- Sanofi
- Stryker
- Zimmer Biomet
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Orthobiologics market
- Product
- Bone Morphogenetic Proteins
- Demineralized Bone Matrix
- Synthetic Bone Substitutes
- Viscosupplements
- Allografts
- Stem cell
- Others
- Application
- Spinal Fusion
- Trauma Repair
- Reconstructive Surgeries
- Others
- End-user
- Hospitals
- Orthopedic Clinics
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7435
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
Blog: https://qyresearchmedical.com/